Literature DB >> 21853352

Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.

Hee Jeong Kim1, Wonshik Han, On Vox Yi, Hee Chul Shin, Soo-Kyung Ahn, Beom Seok Koh, Hyeong-Gon Moon, Jong Han You, Byung Ho Son, Sei Hyun Ahn, Dong-Young Noh.   

Abstract

Young breast cancer patients are more likely than old patients to experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS). However, the pathological processes underlying this relationship have not been elucidated. We investigated the effect of young age on IBTR in a Korean cohort of women with different molecular subtypes of breast cancer. We analyzed data of 2,102 consecutive breast cancer patients who underwent BCS and post-surgical radiation therapy (RT) at two Korean institutions between 2000 and 2005. Patients were classified as young (≤ 40 years; N = 513) or old (> 40 years; N = 1,589). Breast cancer subtype was determined by estrogen receptor (ER), progesterone receptor (PR), and HER2. Median follow-up duration was 61 months. The 5-year IBTR rate was 3.4% in young patients and 1.1% in old patients (P < 0.001). Univariate analysis indicated that IBTR rate in young patients with luminal A and HER2 subtypes was significantly greater than in old patients with these subtypes (P = 0.015 and P < 0.001, respectively). Multivariate analysis, which used luminal A subtype in old patients as reference, indicated that HER2 subtype in young patients was associated with increased risk of IBTR (hazard ratio, HR = 12.24; 95% CI: 2.54-57.96). Among old patients, HER2 subtype was not associated with increased IBTR. In conclusion, young women had a higher rate of IBTR after BCS and RT than old women. This difference is mainly among women with HER2 subtype. Aggressive local control and adjuvant therapy should be considered for young women with HER2 subtype breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21853352     DOI: 10.1007/s10549-011-1736-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

Review 1.  Breast cancer in young women: an overview.

Authors:  Zoi Anastasiadi; Georgios D Lianos; Eleftheria Ignatiadou; Haralampos V Harissis; Michail Mitsis
Journal:  Updates Surg       Date:  2017-03-04

Review 2.  Breast cancer under age 40: a different approach.

Authors:  D Ribnikar; J M Ribeiro; D Pinto; B Sousa; A C Pinto; E Gomes; E C Moser; M J Cardoso; F Cardoso
Journal:  Curr Treat Options Oncol       Date:  2015-04

3.  Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study.

Authors:  Damiano Gentile; Andrea Sagona; Ruggero Spoto; Davide Franceschini; Stefano Vaccari; Valeriano Vinci; Ersilia Biondi; Lorenzo Scardina; Corrado Tinterri
Journal:  Eur J Breast Health       Date:  2022-10-01

Review 4.  Extent of primary breast cancer surgery: standards and individualized concepts.

Authors:  Joerg Heil; Valerie Fuchs; Michael Golatta; Sarah Schott; Markus Wallwiener; Christoph Domschke; Peter Sinn; Michael P Lux; Christof Sohn; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2012-10       Impact factor: 2.860

Review 5.  Effects of age on the detection and management of breast cancer.

Authors:  Andrew McGuire; James A L Brown; Carmel Malone; Ray McLaughlin; Michael J Kerin
Journal:  Cancers (Basel)       Date:  2015-05-22       Impact factor: 6.639

Review 6.  Unique features of young age breast cancer and its management.

Authors:  Han-Byoel Lee; Wonshik Han
Journal:  J Breast Cancer       Date:  2014-12-26       Impact factor: 3.588

7.  The efficacy of molecular subtyping in predicting postoperative recurrence in breast-conserving therapy: a 15-study meta-analysis.

Authors:  Jing Chen; Peng Jiang; Han-Jin Wang; Jia-Yi Zhang; Yang Xu; Mu-Hong Guo; Bin Zhang; Chong-Yin Tang; Hong-Yong Cao; Shui Wang
Journal:  World J Surg Oncol       Date:  2014-07-15       Impact factor: 2.754

8.  Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery.

Authors:  Jong Ho Cheun; Jiyoung Won; Ji Gwang Jung; Hong Kyu Kim; Wonshik Han; Han Byoel Lee
Journal:  J Breast Cancer       Date:  2021-06       Impact factor: 3.588

9.  HVEM gene polymorphisms are associated with sporadic breast cancer in Chinese women.

Authors:  Dalin Li; Zhenkun Fu; Shuang Chen; Weiguang Yuan; Yanhong Liu; Liqun Li; Da Pang; Dianjun Li
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

10.  HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.

Authors:  Haixia Jia; Weijuan Jia; Yaping Yang; Shunrong Li; Huiyi Feng; Jieqiong Liu; Nanyan Rao; Liang Jin; Jiannan Wu; Ru Gu; Liling Zhu; Kai Chen; Heran Deng; Yunjie Zeng; Qiang Liu; Erwei Song; Fengxi Su
Journal:  World J Surg Oncol       Date:  2014-09-20       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.